Oxoglutaric acid
|
Basic information |
| Metabolite name | Oxoglutaric acid |
 | HMDB0000208 |
 |
C00026 |
 |
51 |
| Synonyms | 2-oxoglutarate; |
| No. of studies | 40 |
|
Basic information |
| Metabolite name | Oxoglutaric acid |
| HMDB0000208 |
|
C00026 |
|
51 |
| Synonyms | 2-oxoglutarate; |
| No. of studies | 40 |
|
Relationship between Oxoglutaric acid and depression (count: 40) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M049 | Type2 | xiaoyansan treatment 8-week vs. baseline | Urine | Human | Up |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Down |
| Study M078 | Type1 | CORT model group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M614 | Type2 | CUMS + resistance training group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Up |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Up |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Down |
| Study M768 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M768 | Type2 | depression group, after vs. before fluoxetine treatment | Serum | Human | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Urine | Wistar rat | Down |
| Study M849 | Type1 | CUMS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |